 Leukemia, Myelogenous, Chronic, BCR-ABL Positive
"Leukemia, Myelogenous, Chronic, BCR-ABL Positive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Descriptor ID |
D015464
|
| MeSH Number(s) |
C04.557.337.539.250 C15.378.190.636.370
|
| Concept/Terms |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Chronic Myelogenous
- Leukemia, Chronic Myeloid
- Leukemia, Granulocytic, Chronic
- Leukemia, Myelocytic, Chronic
- Leukemia, Myelogenous, Chronic
- Leukemia, Myelogenous, Ph1 Positive
- Leukemia, Myelogenous, Ph1-Positive
- Leukemia, Myeloid, Chronic
- Leukemia, Myeloid, Ph1 Positive
- Leukemia, Myeloid, Ph1-Positive
- Leukemia, Myeloid, Philadelphia Positive
- Leukemia, Myeloid, Philadelphia-Positive
- Myelocytic Leukemia, Chronic
- Chronic Myelocytic Leukemia
- Chronic Myelocytic Leukemias
- Leukemia, Chronic Myelocytic
- Leukemias, Chronic Myelocytic
- Myelocytic Leukemias, Chronic
- Myelogenous Leukemia, Chronic
- Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemias
- Leukemias, Chronic Myelogenous
- Myelogenous Leukemias, Chronic
- Myelogenous Leukemia, Ph1-Positive
- Leukemia, Ph1-Positive Myelogenous
- Leukemias, Ph1-Positive Myelogenous
- Myelogenous Leukemia, Ph1 Positive
- Myelogenous Leukemias, Ph1-Positive
- Ph1-Positive Myelogenous Leukemia
- Ph1-Positive Myelogenous Leukemias
- Myeloid Leukemia, Chronic
- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemias
- Leukemias, Chronic Myeloid
- Myeloid Leukemias, Chronic
- Myeloid Leukemia, Ph1-Positive
- Leukemia, Ph1-Positive Myeloid
- Leukemias, Ph1-Positive Myeloid
- Myeloid Leukemia, Ph1 Positive
- Myeloid Leukemias, Ph1-Positive
- Ph1-Positive Myeloid Leukemia
- Ph1-Positive Myeloid Leukemias
- Myeloid Leukemia, Philadelphia-Positive
- Leukemia, Philadelphia-Positive Myeloid
- Leukemias, Philadelphia-Positive Myeloid
- Myeloid Leukemia, Philadelphia Positive
- Myeloid Leukemias, Philadelphia-Positive
- Philadelphia-Positive Myeloid Leukemia
- Philadelphia-Positive Myeloid Leukemias
- Granulocytic Leukemia, Chronic
- Chronic Granulocytic Leukemia
- Chronic Granulocytic Leukemias
- Granulocytic Leukemias, Chronic
- Leukemia, Chronic Granulocytic
- Leukemias, Chronic Granulocytic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelogenous, Chronic, BCR-ABL Positive".
This graph shows the total number of publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in UAMS Profiles by year, and whether "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 | | 2021 | 2 | 0 | 2 | | 2019 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 | | 2017 | 1 | 1 | 2 | | 2016 | 2 | 0 | 2 | | 2014 | 2 | 1 | 3 | | 2013 | 3 | 0 | 3 | | 2009 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2007 | 2 | 1 | 3 | | 2005 | 2 | 0 | 2 | | 2004 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 1998 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1994 | 2 | 1 | 3 | | 1993 | 0 | 1 | 1 | | 1992 | 1 | 0 | 1 | | 1991 | 2 | 0 | 2 | | 1989 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in Profiles over the past ten years.
-
Ma J, Pettit N, Talburt J, Wang S, Weissman SM, Yang MQ. Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia. Int J Mol Sci. 2022 Nov 18; 23(22).
-
Fenu E, O'Neill SS, Insuasti-Beltran G. BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses. Int J Lab Hematol. 2021 Dec; 43(6):1458-1464.
-
Antwi-Amoabeng D, Ghuman J, Ghuman J, Beutler BD, Ulanja MB, Kuriakose K, Bowman A. Ponatinib-associated panniculitis: Case report and review of the literature. Cancer Treat Res Commun. 2021; 27:100357.
-
Utuama O, Mukhtar F, Pham YT, Dabo B, Manani P, Moser J, Michael-Asalu A, Tran CT, Le LC, Le TV, Vu KT, Park JY, Boffetta P, Zheng W, Shu XO, Luu HN. Racial/ethnic, age and sex disparities in leukemia survival among adults in the United States during 1973-2014 period. PLoS One. 2019; 14(8):e0220864.
-
Yang MQ, Weissman SM, Yang W, Zhang J, Canaann A, Guan R. MISC: missing imputation for single-cell RNA sequencing data. BMC Syst Biol. 2018 12 14; 12(Suppl 7):114.
-
Flores-Lopez G, Moreno-Lorenzana D, Ayala-Sanchez M, Aviles-Vazquez S, Torres-Martinez H, Crooks PA, Guzman ML, Mayani H, Ch?vez-Gonz?lez A. Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species. J Cell Mol Med. 2018 10; 22(10):4899-4912.
-
Mack J, Mian A. Case 5: Fever and Hypoxia in a 17-year-old Boy Undergoing Cancer Chemotherapy. Pediatr Rev. 2017 May; 38(5):237.
-
Kreys ED, Frei CR, Villarreal SM, Bollinger MJ, Jones X, Koeller JM. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans. Pharmacotherapy. 2017 03; 37(3):278-286.
-
Wang H, Xie B, Kong Y, Tao Y, Yang G, Gao M, Xu H, Zhan F, Shi J, Zhang Y, Wu X. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3. Oncotarget. 2016 Apr 05; 7(14):18638-50.
-
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|